{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T18:01:53Z","timestamp":1764784913710,"version":"3.40.5"},"reference-count":21,"publisher":"Becaris Publishing Limited","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:p>\n            <jats:bold>Background:<\/jats:bold>\n            Relative overall survival (OS) estimates reported in the MAVORIC trial are potentially confounded by a high proportion of patients randomized to vorinostat switching to mogamulizumab; furthermore, vorinostat is not used in clinical practice in the UK.\n            <jats:bold>Methods:<\/jats:bold>\n            Three methods were considered for crossover adjustment. Survival post-crossover adjustment was compared with data from the Hospital Episode Statistics (HES) to contextualize estimates.\n            <jats:bold>Results:<\/jats:bold>\n            Following adjustment, the OS hazard ratio for mogamulizumab versus vorinostat was 0.42 (95% CI: 0.18, 0.98) using the method considered most appropriate based on an assessment of assumptions and comparison with HES.\n            <jats:bold>Conclusions:<\/jats:bold>\n            OS of mogamulizumab relative to vorinostat may be underestimated in MAVORIC due to the presence of crossover. The HES database was used to validate this adjustment.\n          <\/jats:p>","DOI":"10.2217\/cer-2022-0070","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T09:19:36Z","timestamp":1654766376000},"page":"805-813","source":"Crossref","is-referenced-by-count":4,"title":["Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and S\u00e9zary syndrome"],"prefix":"10.57264","volume":"11","author":[{"given":"Neil","family":"Hawkins","sequence":"first","affiliation":[{"name":"Visible Analytics, Oxford, OX2 0DP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1236-1327","authenticated-orcid":false,"given":"Noemi","family":"Muszbek","sequence":"additional","affiliation":[{"name":"Visible Analytics, Oxford, OX2 0DP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4430-0262","authenticated-orcid":false,"given":"Rachel","family":"Evans","sequence":"additional","affiliation":[{"name":"Visible Analytics, Oxford, OX2 0DP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Dequen-O'Byrne","sequence":"additional","affiliation":[{"name":"Visible Analytics, Oxford, OX2 0DP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trefor","family":"Jones","sequence":"additional","affiliation":[{"name":"Payer Value and Patient Access, Kyowa Kirin, Marlow, SL7 1HZ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"McNamara","sequence":"additional","affiliation":[{"name":"Payer Value and Patient Access, Kyowa Kirin, Marlow, SL7 1HZ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"31","key":"e_1_3_4_3_2","doi-asserted-by":"crossref","first-page":"4730","DOI":"10.1200\/JCO.2009.27.7665","article-title":"Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal","volume":"28","author":"Agar NS","year":"2010","unstructured":"Agar NS, Wedgeworth E, Crichton S Survival outcomes and prognostic factors in mycosis fungoides\/S\u00e9zary syndrome: validation of the revised International Society for Cutaneous Lymphomas\/European Organisation for Research and Treatment of Cancer staging proposal. J. Clin. Oncol. 28(31), 4730\u20134739 (2010).","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"e_1_3_4_4_2","first-page":"857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim YH","year":"2003","unstructured":"Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch. Dermatol. 139(7), 857\u2013866 (2003).","journal-title":"Arch. Dermatol."},{"issue":"18","key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1158\/1078-0432.CCR-12-0604","article-title":"Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009","volume":"18","author":"Talpur R","year":"2012","unstructured":"Talpur R, Singh L, Daulat S Long-term outcomes of 1,263 patients with mycosis fungoides and S\u00e9zary syndrome from 1982 to 2009. Clin. Cancer Res. 18(18), 5051\u20135060 (2012).","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.V97.3.624","article-title":"Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma","volume":"97","author":"Scarisbrick JJ","year":"2001","unstructured":"Scarisbrick JJ, Whittaker S, Evans AV Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood 97(3), 624\u2013630 (2001).","journal-title":"Blood"},{"unstructured":"NHS Digital. Hospital Episode Statistics (HES) (2019). https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics","key":"e_1_3_4_7_2"},{"unstructured":"Public Health England. National cancer registration and analysis services. Registration of cutaneous t-cell lymphoma (CTCL) in England (2016). www.ncin.org.uk\/view?rid=3275","key":"e_1_3_4_8_2"},{"key":"e_1_3_4_9_2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2017.02.027","article-title":"European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 update 2017","volume":"77","author":"Trautinger F","year":"2017","unstructured":"Trautinger F, Eder J, Assaf C European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome \u2013 update 2017. Eur. J. Cancer 77, 57\u201374 (2017).","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"e_1_3_4_10_2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjd.17240","article-title":"British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018","volume":"180","author":"Gilson D","year":"2019","unstructured":"Gilson D, Whittaker SJ, Child FJ British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br. J. Dermatol. 180(3), 496\u2013526 (2019).","journal-title":"Br. J. Dermatol."},{"issue":"9","key":"e_1_3_4_11_2","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim YH","year":"2018","unstructured":"Kim YH, Bagot M, Pinter-Brown L Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 19(9), 1192\u20131204 (2018).","journal-title":"Lancet Oncol."},{"issue":"9","key":"e_1_3_4_12_2","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic M","year":"2001","unstructured":"Duvic M, Hymes K, Heald P Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J. Clin. Oncol. 19(9), 2456\u20132471 (2001).","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen EA","year":"2007","unstructured":"Olsen EA, Kim YH, Kuzel TM Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25(21), 3109\u20133115 (2007).","journal-title":"J. Clin. Oncol."},{"unstructured":"European Medicines Agency. Poteligeo: European public assessment report (EPAR) (2019). www.ema.europa.eu\/en\/medicines\/human\/EPAR\/poteligeo","key":"e_1_3_4_14_2"},{"unstructured":"European Medicines Agency. Summary of product characteristics. Poteligeo \u00ae (mogamulizumab) (2019). www.ema.europa.eu\/en\/medicines\/human\/EPAR\/poteligeo","key":"e_1_3_4_15_2"},{"unstructured":"European Medicines Agency (EMA). Question and answer on adjustment for cross-over in estimating effects in oncology trials (2018). www.ema.europa.eu\/en\/documents\/scientific-guideline\/question-answer-adjustment-cross-over-estimating-effects-oncology-trials_en.pdf","key":"e_1_3_4_16_2"},{"issue":"3","key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jval.2019.10.015","article-title":"Adjusting for treatment switching in oncology trials: a systematic review and recommendations for reporting","volume":"23","author":"Sullivan TR","year":"2020","unstructured":"Sullivan TR, Latimer NR, Gray J, Sorich MJ, Salter AB, Karnon J. Adjusting for treatment switching in oncology trials: a systematic review and recommendations for reporting. Value Health 23(3), 388\u2013396 (2020).","journal-title":"Value Health"},{"unstructured":"Kyowa Kirin Pharmaceutical Development Inc. Open-label multi-center randomized study of anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) versus vorinostat in subjects with previously treated cutaneous T-cell lymphoma (2012). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01728805","key":"e_1_3_4_18_2"},{"key":"e_1_3_4_19_2","first-page":"57","article-title":"NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching","author":"Latimer NR","year":"2014","unstructured":"Latimer NR, Abrams KR. NICE DSU technical support document 16: adjusting survival time estimates in the presence of treatment switching. Decision Support Unit, ScHARR 57 (2014).","journal-title":"Decision Support Unit, ScHARR"},{"key":"e_1_3_4_20_2","volume-title":"R: A Language and Environment for Statistical Computing.","author":"R Core Team","year":"2020","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria (2020). www.R-project.org\/"},{"unstructured":"National Institute for Health and Care Excellence (NICE). Mogamulizumab for previously treated mycosis fungoides and S\u00e9zary syndrome [ID1405] \u2013 committee papers (2020). www.nice.org.uk\/guidance\/gid-ta10305\/documents\/committee-papers","key":"e_1_3_4_21_2"},{"issue":"32","key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick JJ","year":"2015","unstructured":"Scarisbrick JJ, Prince HM, Vermeer MH Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J. Clin. Oncol. 33(32), 3766\u20133773 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1177\/0962280214557578","article-title":"Adjusting for treatment switching in randomised controlled trials \u2013 a simulation study and a simplified two-stage method","volume":"26","author":"Latimer NR","year":"2017","unstructured":"Latimer NR, Abrams KR, Lambert PC Adjusting for treatment switching in randomised controlled trials \u2013 a simulation study and a simplified two-stage method. Stat. Methods Med. Res 26(2), 724\u2013751 (2017).","journal-title":"Stat. Methods Med. Res"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2022-0070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:47:00Z","timestamp":1679230020000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2022-0070"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.2217\/cer-2022-0070"],"URL":"https:\/\/doi.org\/10.2217\/cer-2022-0070","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}